Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Tabalumab in SLE (Illuminate-X)
NCT01488708Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2012
- Primary completion
- Oct 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tabalumab in systemic lupus erythematosus (SLE), sponsored by Eli Lilly and Company. Started Jan 2012; status: terminated.
02
Drugs
tabalumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT01488708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01488708.